1,047 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Choreo LLC

Choreo LLC bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,047 shares of the biopharmaceutical company’s stock, valued at approximately $920,000.

Several other institutional investors have also added to or reduced their stakes in the business. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $26,000. Fortitude Family Office LLC purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $31,000. MCF Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares during the period. Criterion Capital Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $37,000. Finally, Sutton Wealth Advisors Inc. increased its stake in shares of Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 13 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 854 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 26th. The stock was sold at an average price of $979.25, for a total transaction of $836,279.50. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at $1,353,323.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Bonnie L. Bassler sold 854 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $979.25, for a total transaction of $836,279.50. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,353,323.50. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the sale, the executive vice president now owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Insiders have sold 10,095 shares of company stock valued at $9,664,476 in the last quarter. 8.83% of the stock is owned by insiders.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $903.48 on Thursday. The stock has a market cap of $99.17 billion, a PE ratio of 26.00, a P/E/G ratio of 2.55 and a beta of 0.17. Regeneron Pharmaceuticals, Inc. has a 12 month low of $684.80 and a 12 month high of $998.33. The company has a 50-day moving average price of $944.78 and a 200 day moving average price of $895.25. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same quarter in the previous year, the business earned $10.96 earnings per share. The company’s revenue for the quarter was up .6% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current year.

Analysts Set New Price Targets

REGN has been the subject of several recent analyst reports. Bank of America upped their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective for the company. TD Cowen lifted their target price on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. BMO Capital Markets upped their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $977.77.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.